Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EP MedSystems settlement

This article was originally published in The Gray Sheet

Executive Summary

Cardiac electrophysiology device firm pays the U.S. Department of the Treasury $33,000 to resolve charges that it sold products to restricted countries including Iran in 2004 and earlier without governmental authorization. With the March 28 settlement, under which the firm does not admit guilt, EP MedSystems deems the related issues to be "closed." The company paid $244,000 to settle with the U.S. Department of Commerce last November (1"The Gray Sheet" Nov. 13, 2006, In Brief)...

You may also be interested in...

EP MedSystems settlement

Cardiac electrophysiology device maker will pay a fine of $244,000 to settle charges by the U.S. Department of Commerce that the firm sold products to restricted countries including Iran without governmental authorization. EP MedSystems admits no wrongdoing. The company previously reported that an internal audit uncovered inaccurate statements by former CEO Reinhard Schmidt during DoC's investigation (1"The Gray Sheet" Oct. 17, 2005, p. 16). Related issues have yet to be closed with the Treasury Department and Securities & Exchange Commission...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts